Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma

NCT01250470 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

9

Enrollment

OTHER

Sponsor class

Conditions

Anaplastic Astrocytoma
Anaplastic Oligoastrocytoma
Anaplastic Oligodendroglioma
Giant Cell Glioblastoma
Glioblastoma
Gliosarcoma
Mixed Glioma
Recurrent Brain Neoplasm

Interventions

OTHER: Laboratory Biomarker Analysis
DRUG: Montanide ISA-51/Survivin Peptide Vaccine
BIOLOGICAL: Sargramostim

Sponsor

Roswell Park Cancer Institute

Collaborators

[object Object]